Treatment-resistant schizophrenia: Evidence-based strategies

Mens Sana Monographs

Volumn 10, Issue 1, 2012, Pages 20-32

  Englisch, Susanne ^a   Zink, Mathias ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Add on; Augmentation; Combination; Polypharmacy; Schizophrenia; Treatment resistance

Indexed keywords

EID: 84861302256     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.91588     Document Type: Review

References (35)

1. Aitchison KJ, Mir A, Shivakumar K, McAllister VD, O'Keane V, McCrone P. Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. J Psychopharmacol 2011;25:675-84. PMID: 20176773
2. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schwarz SF, Leucht S. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;11:CD006633. PMID: 21069690
3. Assion HJ, Reinbold H, Lemanski S, Bsilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial, Pharmacopsychiatry 2008;41:24-8. PMID: 18203048 (Pubitemid 351195889)
4. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010;71:103-8. PMID: 19895781
5. Barbui C, Accordini S, Nose M, Stroup S, Purgato M, Girlanda F, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol 2011;31:266-73. PMID: 21508849
6. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacol 2009;34:1330-8. PMID: 19052541
7. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 2010;25:179-86. PMID: 20196186
8. Citrome L. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: Useful strategy or exercise in futility? J Clin Psychiatry 2009;70:932-3. PMID: 19573487
9. Englisch S, Enning F, Grosshans M, Marquardt L, Waltereit R, Zink M. Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapinemonotherapy. Clin Neuropharmacol 2010a;33:227-9. PMID: 20838213
10. Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010b;30:437-40. PMID: 20531222
11. Englisch S, Knopf U, Scharnholz B, Kuwilsky A, Deuschle M, Zink M. Duloxetine for major depressive episodes in the course of psychotic disorders: An observational clinical trial. J Psychopharmacol 2009;23:875-82. PMID: 18583440
12. Englisch S, Meyer-Lindenberg A, Zink M. Risks and benefits of Bupropion treatment in Schizophrenia: A meta-analysis. J Psychopharmacol 2011;in press.
13. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011;168:702-8. PMID: 21536693
14. Fleischhacker W, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13:1115-25. PMID: 20459883
15. Gomez JV, Fuste G, Coronas R, Benito N, Barbero JD, Domenech C, et al. Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Curr Drug Safety 2008;3:210-5. PMID: 18691004
16. Kuwilsky A, Krumm B, Englisch S, Dressing H, Zink M. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20. PMID: 20589598
17. Lerma-Carrillo I, de Pablo BS, del Pozo ML, Pascual-Pinazo F, Molina JD, Baca-Garcia E. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 2008;31:319-32. PMID: 19050409
18. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007;3:CD003834. PMID: 17636738
19. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2007;:CD001258. PMID: 17636660
20. Muscatello MR, Bruno A, Pandolfo G, Mico U, Bellinghieri PM, Scimeca G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 2011;25:667-74. PMID: 20615930
21. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123:411-22. PMID: 21534935
22. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: Preponderance of off-label drug use. PLoS One 2008;3:e3150. PMID: 18781198
23. Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 2011;41:2361-74.
24. Schirmbeck F, Zink M, Clozapine-induced obsessive-compulsive symptoms in schizophrenia: A critical review. Curr Neuropharmacol 2011; in press.
25. Se HK, Dong CJ, Yong MA, Yong SK. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: A case series. J Psychopharmacol 2010;24:981-6. PMID: 19942641
26. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br J Psychiatry 2010;197:174-9. PMID: 20807960
27. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2011;35:1080-6. PMID: 21402120
28. Taylor DM, Smith L, Gee SH, Jimmi N. Augmentation of clozapine with a second antipsychotic: a meta-analysis. Acta Psychiatr Scand 2012;125:15-24. PMID: 22077319
29. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009;374:620-7. PMID: 19595447
30. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res 2009;109:10-4. PMID: 19186030
31. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia: A critical review and meta-analysis. Curr Pharmaceut Design 2010;16:522-37. PMID: 19909229
32. Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010;1:CD008125. PMID: 20091661
33. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophr Res 2009;113:1-11. PMID: 19524406
34. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11. PMID: 20051861
35. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomized controlled clinical trial. J Psychopharmacol 2009;23:305-14. PMID: 18562423